Independent pharmacy is a global category.
The problems are more universal than the English-language trade press acknowledges.
The solutions are more transferable than most owners realize.
Why a global perspective matters for your specific market
If you operate in the United States, the DIR fee problem feels American.
It is not.
The underlying dynamic — a powerful intermediary extracting margin from independent pharmacy through mechanisms that are complex, opaque, and largely outside the individual owner's control — appears in every market with a third-party payment system for pharmaceuticals.
The specific mechanism changes. The structural tension does not.
Conversely, some of the most useful solutions to problems facing US independent pharmacy are being developed right now in markets that the American trade press does not cover.
Pharmacist prescribing authority in Canada. Clinical service payment structures in the UK. The cash-pay market dynamics in Nigeria. The community pharmacy primary care integration happening in Australia.
Understanding these developments is not an academic exercise.
It is competitive intelligence about where pharmacy is going.
United Kingdom: the clinical services inflection point
The United Kingdom's community pharmacy sector operates under the NHS Community Pharmacy Contractual Framework, which governs what community pharmacists can do and what they are paid for doing it.
For most of the past decade, that framework has been a source of financial pressure rather than opportunity. NHS funding for community pharmacy dispensing has not kept pace with cost increases. Independent owners in England describe margins that leave minimal resilience.
What changed in January 2024 is significant.
The Pharmacy First program gives community pharmacists in England the authority to assess and treat patients for seven common conditions without a GP referral. Sinusitis. Sore throat. Earache. Infected insect bite. Impetigo. Shingles. Uncomplicated urinary tract infections.
This is not a minor adjustment.
This is the largest expansion of community pharmacy clinical scope within the NHS in a generation.
The payment structure for Pharmacy First consultations is separate from the standard dispensing payment. A pharmacy completing consultations at meaningful volume generates clinical service revenue that is structurally different from dispensing reimbursement — it is paid per completed consultation, not per prescription, and it is not subject to the same intermediary pressure as dispensing reimbursement.
The independent pharmacies in England that have invested in the clinical infrastructure to deliver Pharmacy First at volume are seeing a meaningful shift in their revenue composition.
The ones that approached it as an administrative burden rather than a revenue opportunity have not.
The lesson for owners in other markets is direct.
When your regulatory environment creates a new clinical service payment mechanism, the pharmacies that invest in delivery capacity first gain a compounding advantage over those that wait to see whether the payment is worth the effort.
Nigeria: building formal pharmacy in a market with enormous demand
Nigeria has a population of over 200 million people, a rapidly growing middle class, a documented shortage of accessible formal pharmaceutical services in most of the country, and a regulatory environment that is increasingly drawing a clear line between licensed pharmacy professionals and informal drug vendors.
The Pharmacists Council of Nigeria has been strengthening enforcement of the requirement that pharmaceutical retail be conducted by or under the supervision of a registered pharmacist in a licensed premises. This regulatory direction is creating formalization pressure across a market that has historically been largely informal.
For credentialed independent pharmacy owners operating in Nigeria — or for owners outside Nigeria considering what an emerging pharmacy market looks like before chains establish dominance — the dynamics are worth understanding.
The cash-pay majority means that reimbursement intermediary complexity, which consumes significant management bandwidth for US and UK independent pharmacy owners, is largely absent. The margin pressure comes from different sources: supply chain reliability, counterfeit product risk, price competition from informal vendors, and the cost of maintaining licensed premises.
The demand side is genuinely strong and genuinely underserved.
A licensed independent pharmacy in a Nigerian neighborhood without other formal pharmacy access is not competing for market share.
It is filling a gap that is otherwise unfilled.
That is a different business position than independent pharmacy in most Western markets.
Canada: the prescribing authority advantage
Canadian pharmacists have historically operated under a more constrained scope of practice than their clinical training justifies.
That is changing rapidly.
Alberta has gone furthest, with pharmacist prescribing authority now covering a substantial list of conditions including urinary tract infections, oral contraceptives, smoking cessation, and several other common acute and chronic condition categories. Ontario, British Columbia, and Saskatchewan have expanded prescribing authority in varying degrees.
The strategic implication for independent pharmacy owners in provinces with expanded prescribing authority is not simply additional revenue from prescribing consultations.
It is a fundamental repositioning of what an independent pharmacy is.
A pharmacy where the pharmacist can assess, diagnose, and treat a urinary tract infection is not a dispensing business with an added service.
It is a primary care access point that also dispenses medications.
That repositioning changes the patient relationship, changes the prescriber relationship, and changes the community value proposition of the pharmacy in ways that are difficult for chains operating on dispensing throughput models to replicate.
The independent pharmacies in Canada building toward that clinical identity earliest — rather than treating prescribing authority as a peripheral add-on — are building a structural advantage that is genuinely durable.
Australia: the PBS pressure and the clinical services response
Australian independent pharmacy operates primarily within the Pharmaceutical Benefits Scheme, which governs the prices the government pays for dispensed medications and the conditions under which community pharmacies can dispense them.
The PBS funding environment has been a consistent source of tension. Independent owners describe PBS remuneration that has not kept pace with operating cost increases and that leaves limited room for investment in new services.
The clinical services response that the highest-performing Australian independents are pursuing involves the government-funded clinical programs that sit outside the PBS dispensing structure.
The MedsCheck program provides payment for structured medication reviews for patients taking five or more regular medications. The Diabetes MedsCheck provides a similar service specifically for diabetes patients. Both are underused relative to the eligible patient populations in most community pharmacy catchment areas.
The Home Medicines Review program, in which a pharmacist conducts a comprehensive medication review in the patient's home as part of a collaborative care model, generates higher per-review payment than MedsCheck and serves a patient population — complex, housebound, high-risk — where pharmacist intervention has clear clinical value.
The Australian independents generating meaningful clinical service revenue are the ones that have built the operational systems to identify eligible patients, conduct reviews at volume, and bill correctly — the identical discipline that the MTM billing framework describes for US pharmacies.
The specific program names are different. The operational framework is the same.
The cross-market insight that matters most
In every market where independent pharmacy is under financial pressure, the pharmacies that are building durable businesses are building them in the same direction.
Away from pure dispensing dependence. Toward clinical service revenue. Toward patient relationships that chains cannot replicate. Toward specific patient populations where their pharmacy provides genuine irreplaceable value.
The specific programs that enable this are different in every market.
Pharmacy First in England. Prescribing authority in Canadian provinces. MedsCheck in Australia. MTM in the United States. Cash-pay clinical service delivery in Nigeria.
The strategic direction is identical.
Pharmacy is moving from a dispensing business into a clinical services business.
The independents building toward that model earliest in every market will have the clearest advantage as that shift continues.
What owners in different markets can learn from each other
US owners watching Canada's prescribing authority expansion can see where US pharmacy scope is likely to move, and can invest in clinical infrastructure now rather than after the regulatory change.
UK owners building Pharmacy First clinical delivery capacity are developing a service model that mirrors what US pharmacies are doing with MTM — and the operational lessons transfer directly.
Nigerian owners building formal pharmacy businesses in high-demand, low-competition markets are building cash-pay clinical service models that may become increasingly relevant as US and UK reimbursement pressure intensifies.
Australian owners developing MedsCheck volume are solving the same operational problem that US MTM programs solve: building a recurring system that identifies eligible patients and delivers a structured clinical service at consistent volume.
The trade press does not connect these dots because it does not cover all these markets in the same publication.
BlinkHub does.
Read next on Blinkerhub:
The clinical services direction that every market is moving toward begins with the revenue streams that are most accessible right now. The MTM billing guide covers the US version. The physician relationship strategy covers a model that works in any cash-pay or insurance market.
And if the question of whether your specific independent pharmacy has a durable future is what you most need answered, the viability analysis covers every major market directly.
Blinkerhub is a free weekly intelligence newsletter for independent pharmacy owners worldwide. Not affiliated with any PBM, chain pharmacy, trade association, or pharmacy software vendor. Published every Tuesday at pharmacy.blinkerhub.com.
Regulatory frameworks, clinical service payment structures, and pharmacy scope of practice rules vary by country, state, and province. Verify current requirements with your national or regional regulatory authority.